Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850331 | 1.00 | ACE (0.47) | ACEP2RX7 | |
| SCHEMBL1587617 | 1.00 | ACE (0.47) | ACEP2RX7 | |
| SCHEMBL647325 | 1.00 | ACE (0.47) | ACEP2RX7 | |
| Ammonia Solution, Strong SCHEMBL11295703 | 0.98 | ACE (0.46) | ACEP2RX7 | |
| SCHEMBL16339447 | 0.88 | P2RX7 (0.44) | ACEP2RX7 | |
| SCHEMBL30813130 | 0.88 | P2RX7 (0.44) | ACEP2RX7 | |
| SCHEMBL16339048 | 0.88 | P2RX7 (0.44) | ACEP2RX7 | |
| SCHEMBL18212792 | 0.86 | ACE (0.44) | ACEP2RX7 | |
| SCHEMBL13949148 | 0.83 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL18101128 | 0.83 | P2RX7 (0.45) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338193-A1 | CHIRAL 1-(4-METHYLPHENYLMETHYL)-5-OXO--PYRROLIDINE-2-CARBOXAMIDES AS INHIBITORS OF COLLAGEN INDUCED PLATELET ACTIVATION AND ADHESION | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-12-19 | — | — | US | claimed |
| US-20100163070-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | claimed |
| US-20100065492-A1 | Compositions And Methods For Separating Enantiomers | WATERS TECHNOLOGIES CORPORATION (US) | 2010-03-18 | — | — | US | claimed |
| US-7628920-B2 | Compositions and methods for separating enantiomers | WATERS TECHNOLOGIES CORPORATION (US) | 2009-12-08 | — | — | US | claimed |
| US-20080237130-A1 | Compositions and Methods for Separating Enantiomers | WATERS INVESTMENTS LIMITED (US) | 2008-10-02 | — | — | US | claimed |
| JP-2007532880-A | — | — | 2007-11-15 | — | — | JP | claimed |
| WO-2005099855-A1 | COMPOSITIONS AND METHODS FOR SEPARATING ENANTIOMERS | WATERS INVESTMENTS LIMITED (US) | 2005-10-27 | — | — | WO | claimed |
| WO-2005094854-A1 | MODIFIED NUTRACEUTICAL COMPOSITION | TORBANGUN PTY LTD (AU) | 2005-10-13 | — | — | WO | claimed |
| US-3953352-A | COATING A PYRROLIDONE-CARBOXYLIC ACID COMPOUND | KAO SOAP CO., LTD. (JA) | 1976-04-27 | — | — | US | claimed |
| JP-57170146-A | — | — | None | — | — | JP | disclosed |
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| JP-S57170146-A | CENTRAL SYRUP FOR CONFECTION | LOTTE CO LTD | 1982-10-20 | — | — | JP | disclosed |
| US-4220168-A | Method of moisturizing and maintaining normal moisture level in hair having a normal moisture content | HELENE CURTIS INDUSTRIES, INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4220166-A | Method of restoring normal moisture level to hair with severe moisture deficiency | HELENE CURTIS INDUSTRIES, INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4220167-A | Method of restoring normal moisture level to hair with slight to moderate moisture deficiency | HELENE CURTIS INDUSTRIES, INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-3953352-A | COATING A PYRROLIDONE-CARBOXYLIC ACID COMPOUND | KAO SOAP CO., LTD. (JA) | 1976-04-27 | — | — | US | disclosed |
| US-3932622-A | WATER-IN-OIL EMULSION, DISODIUM OR DIPOTASSIUM SALT OF N-ACETYLGLUTAMTIC ACID | GENERAL FOODS CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ACE 4036/4885P2RX7 4335/4885 |
| US-20130338193-A1 | CHIRAL 1-(4-METHYLPHENYLMETHYL)-5-OXO--PYRROLIDINE-2-CARBOXAMIDES AS INHIBITORS OF COLLAGEN INDUCED PLATELET ACTIVATION AND ADHESION | PLOD1, PLOD3, PLOD2 | ACE 3663/4885P2RX7 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.